Xeloda

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Company:

Approval Status:

Approved April 1998

Specific Treatments:

breast cancer

Find Related Trials for The Following Conditions

General Information

Xeloda has been granted approval under the FDA's accelerated approval program.

Clinical Results

The approval of the Xeloda pill was based on a study involving 43 patients whose cancer no longer responded to conventional treatment. In that group, Xeloda appeared to help shrink tumors in 25% of patients.

In a larger study of 162 patients whose cancer was resistant to normal treatment, Roche reported that tumors shrank by half in almost 20%.

Side Effects

Side effects including diarrhea, nausea, and fatigue were manageable and reversible after discontinuation.